As weight loss leaders boom, one biotech contender abandons its quest with Chapter 7 liquidationnews2023-11-03T15:50:10+00:00November 3rd, 2023|Endpoints News|
Outlook to conduct another trial for wet AMD drug; Cara strikes new royalty dealnews2023-11-03T14:55:35+00:00November 3rd, 2023|Endpoints News|
In early look at ASH abstracts, BeiGene touts Brukinsa data, Cellectis compares in-house CAR-T to CDMO CAR-Tnews2023-11-03T14:50:02+00:00November 3rd, 2023|Endpoints News|
Boehringer Ingelheim plans PhIII chronic kidney disease trial for aldosterone-targeting drug after mid-stage successnews2023-11-03T14:30:48+00:00November 3rd, 2023|Endpoints News|
Novartis’ Pluvicto supply ‘fully unconstrained,’ eyes manufacturing expansionnews2023-11-03T11:28:51+00:00November 3rd, 2023|Endpoints News|
Kronos Bio axes nearly one-fifth of staff to preserve cash for two cancer programsnews2023-11-03T11:16:17+00:00November 3rd, 2023|Endpoints News|
Neumora seeks deals to expand neuro pipeline as CEO leverages M&A experiencenews2023-11-03T11:16:04+00:00November 3rd, 2023|Endpoints News|
Rapport hires CFO Troy Ignelzi from Karuna; Bristol Myers’ new CEO to chair the board next yearnews2023-11-03T10:36:46+00:00November 3rd, 2023|Endpoints News|
Lexeo Therapeutics prices $100M IPO, joins small class of 2023 biotechs on Nasdaqnews2023-11-03T05:16:02+00:00November 3rd, 2023|Endpoints News|
Phathom notches FDA approval for Voquezna to treat erosive GERDnews2023-11-02T20:02:15+00:00November 2nd, 2023|Endpoints News|
